MiraKind 6 and 25 percent banner
•
0 likes•125 views
Our current research focuses on the KRAS-variant: (1) an inherited, genetic marker that has significant implications for women’s health, (2) a predictor of endometriosis, associated infertility, and breast, ovarian and lung cancer, and (3) a biomarker that identifies patients who will uniquely respond to agents used to treat cancer. Please visit MiraKind.org to learn more.
